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Introduction: Lung cancer was a major epidemic in the last decades;
10 to 15% of lung cancer consists of small cell lung cancer (SCLC).
Several changes in the diagnostic and treatment procedures took place
during the last 20 years. This article focuses on trends in incidence,
treatment, and survival of SCLC observed since the 1990s.
Methods: All cases with SCLC diagnosed in 1989 to 2009 in the
Netherlands were included (n  34,100). Follow-up was complete
until January 1, 2010.
Results: The proportion of patients with extensive disease increased
from 47 to 63%. The proportion of patients with limited disease
receiving chemoradiation increased from 22% in 1989 to 2003 to
72% in 2004 to 2009 among those younger than 45 to 59 years, from
15 to 58% among those aged 60 to 74 years, and from 7 to 27%
among those 75 years or older. Among patients with extensive
disease, the proportion receiving chemotherapy remained stable over
time (84, 75, and almost 50% for the above mentioned age groups,
respectively). Significant improvements in 1-year relative survival oc-
curred for patients aged 45 to 59 years, but not for the other age groups.
Relative survival has significantly increased for both stage groups.
Conclusion: Improved staging resulted in improved survival for
both stage groups, whereas survival of the total group has only
significantly improved for patients aged 45 to 59 years. The latter is
possibly related with improved treatment strategies. As survival is
still very poor, prevention of lung cancer remains important.
Key Words: Small cell lung cancer, Trends, Incidence, Treatment,
Survival, Population-based.
(J Thorac Oncol. 2012;7: 227–232)
Lung cancer is now the second most common cancer typein Dutch men and the third most common type in
women (www.ikcnet.nl). In the twentieth century, the
increase in incidence and mortality of lung cancer in the
Netherlands was so dramatic that it can be considered as a
major epidemic.1 Although lung cancer mortality among
men has been decreasing since the mid-1980s, the recent
increase among Dutch women is one of the most prominent
in Europe.2,3
Ten to 15% of all lung cancer patients have small cell
lung cancer (SCLC).4,5 SCLC is an aggressive tumor which is
frequently metastasized at time of diagnosis; median survival
time for patients with limited disease (LD) is approximately
23 months and for those with extensive disease (ED) 8 to 12
months.6 Because SCLC is considered a disseminated dis-
ease, chemotherapy is the cornerstone in the treatment of both
limited and extensive disease. Several studies have reported
an improvement in survival after the introduction of chemo-
therapy in the 1970s.4,7–10 Nowadays, standard treatment for
patients with LD who have a good performance score consists
of combined chemotherapy and radiotherapy, whereas for
those with ED chemotherapy alone is recommended (and
depending on locoregional symptoms also thoracic radiother-
apy). Because of the high probability of brain metastases,
prophylactic cranial irradiation (PCI) for patients with LD is
recommended since the early 2000s.11 This results in better
quality of life. Since the study of Slotman et al.,12 PCI is
also recommended for patients with ED. New treatment
modalities resulted in small improvements in survival in
clinical trials with selected patients, mostly with good
performance status and younger age. The question remains
how these changes in treatment effected survival in daily
practice with unselected patients. This article focuses on
the trends in incidence of SCLC, treatment strategies, and
survival of unselected patients with SCLC in the Nether-
lands since 1989.
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MATERIALS AND METHODS
Data Collection
Population-based data were obtained from the nationwide
Netherlands Cancer Registry (NCR), which started in 1989 and
is maintained and hosted by the regional Comprehensive Cancer
Centers (www.ikcnet.nl). The NCR is based on notification of
all newly diagnosed malignancies in the Netherlands by the
automated pathological archive (PALGA). An additional source
is the national registry of hospital discharge, which accounts for
up to 8% of new cases. Information on patient and tumor
characteristics is obtained routinely from the medical records 6
to 9 months after diagnosis. The quality of the data is high, due
to thorough training of the administrators and computerized
consistency checks at regional and national levels. Com-
pleteness is estimated to be at least 95%.13 Follow-up of
vital status of all patients was calculated as the time from
diagnosis to death or until January 1, 2010. The informa-
tion on vital status was actively obtained from the munic-
ipal registries and from the database of deceased persons
of the Central Bureau for Genealogy.
For this study, all cases with primary SCLC (C34.0-
C34.9 and morphology codes 8041–8045) diagnosed in the
period 1989 to 2009 in the Netherlands were included (n 
34,100). Patients younger than 15 years and older than 95
years at diagnosis were excluded from the survival analysis,
as well as cases diagnosed by autopsy. Treatment and sur-
vival were described for three age groups (45–59 years,
60–74 years, and 75 years or older). The study period was
divided into four categories: 1989 to 1993, 1994 to 1998,
1999 to 2003, and 2004 to 2009. Clinical stage of disease was
classified as limited (tumors confined to one hemithorax
without pleural effusion and no distant metastases) and ex-
tensive (distant metastases in the contralateral chest or at
distant sites and pleural effusion). Treatment of SCLC was
classified as chemotherapy  thoracic radiotherapy (chemo-
radiation, CT  RT), chemotherapy alone, and “no antican-
cer treatment/best supportive care (BSC).” PCI was described
as proportion of those receiving chemotherapy.
Statistical Analyses
Annual incidence and mortality rates for the period
1989 to 2009 were calculated per 100,000 person-years, using
the annual midyear population size as obtained from Statistics
Netherlands. Rates were age-standardized to the European
standard population (European Standardized Rates [ESR]).
Changes were evaluated by calculating the estimated annual
percentage change (EAPC) and the corresponding 95% con-
fidence interval. To calculate this, a regression line was fitted
to the natural logarithm of the rates, using the calendar year
as regressor variable.
Stage at diagnosis and primary treatment was described
as percentages per age group and time period. Differences
between groups were tested with the 2 test. Relative survival
was used as an estimation of disease-specific survival. It
reflects survival of cancer patients, adjusted for survival in
the general population with the same structure for age and
gender. Relative survival is calculated as the ratio of the
observed rates in cancer patients to the expected rates in the
general population.14 Traditional cohort-based relative survival
analysis was used for the period 1989 to 2003, which represents
the real survival of patients diagnosed. Because follow-up for
patients diagnosed in 2004 to 2009 was only available for a few
years, period-based calculation of relative survival analysis was
applied to generate the most up-to-date estimates for this pe-
riod.15 Relative 1-, 3-, and 5-year survival was estimated accord-
ing to gender, stage, age, and period of diagnosis. Survival
trends were quantified as the mean annual percentage change
within 1989 to 2009 estimated by a linear regression model.
RESULTS
Patient Characteristics
Table 1 shows the general characteristics of the pa-
tients. In the time period 1989 to 2009, 34,100 patients were
diagnosed with SCLC: 23,299 (68%) males and 10,801
(32%) females. The male-female ratio decreased from 3.7 in
1989 to 1993 to 1.4 in 2004 to 2009. The median age at
diagnosis increased from 68.1 to 69.3 years among males (p 
0.001) and from 63.6 to 65.6 years among females (p 0.001).
The proportion of patients with unknown stage de-
creased from 12% in 1989 to 1993 to 4% in 2004 to 2009.
Among those with known stage, the proportion of patients
with ED at diagnosis was about 50% until the late 1990s, but
increased to about 65% in 2004 to 2009 (Figure 1). The
proportion of patients with LD was significantly higher
among women (p  0.001). The proportional distribution of
stage did not differ significantly between the age groups.
Trends in Incidence
Figure 2 shows the trends in incidence of SCLC. The
age-standardized incidence rate (ESR) of SCLC among men
decreased from 19 per 100,000 in 1989 to 10 per 100,000 in
2009. The estimated annual percentage change (EAPC) was
–3.8%, 95% CI  4.1, 3.4. Among women, the age-
standardized incidence has increased from 4.3 to 7.0 per
100,000 (EAPC  2.6%, 95% CI  2.3, 2.9).
TABLE 1. Characteristics of Patients with Small Cell Lung
Cancer by Period of Diagnosis
Period of Diagnosis N (%)
1989–1993 1994–1998 1999–2003 2004–2009
Gender
Male 6617 (79) 5737 (72) 5026 (65) 5919 (59)
Female 1789 (21) 2177 (28) 2682 (35) 4153 (41)
Age (yr)
Younger than 45 209 (2) 182 (2) 153 (2) 135 (1)
45–59 1834 (22) 1724 (22) 1833 (24) 2323 (23)
60–74 4635 (55) 4325 (55) 4029 (52) 5194 (52)
75 years or older 1728 (21) 1683 (21) 1693 (22) 2420 (24)
Stage
Limited 3409 (41) 3429 (43) 2863 (37) 3355 (33)
Extensive 3963 (47) 3628 (46) 4159 (54) 6370 (63)
Unknown 1034 (12) 857 (11) 686 (9) 347 (4)
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Trends in Treatment Strategies
Among younger patients with LD diagnosed in 2004 to
2009, the proportion receiving chemoradiation was consider-
ably higher than among those 75 years or older (Figure 3A).
Since the early 1990s, the proportion of patients receiving
chemoradiation has increased from 22 to 72% among those
aged 45 to 59 years, from 15 to 58% among those aged 60 to
74 years, and from 7 to 27% among those 75 years or older
(Figure 3B). In the meantime, the proportion of patients
receiving chemotherapy alone has decreased from 67 to 17%
among those younger than 45 to 59 years, from 72 to 23%
among those aged 60 to 74 years, and from 50 to 33% among
those 75 years or older. Furthermore, the proportion of
patients receiving best supportive care remained stable at 12,
18, and about 40% for those aged 45 to 59, 60 to 74, and 75
years or older, respectively. PCI was introduced in 1999 and
increased to 69% in 2009 in patients aged 45 to 59 years who
had received chemotherapy, 63% in those aged 60 to 74
years, and 42% of those 75 years or older.
Among patients with ED, the proportion receiving
chemotherapy remained stable over time (84, 75, and almost
50% for patients aged 45–59 years, 60–74 years, and 75 years
or older, respectively), but was considerably lower among
those 75 years or older compared with younger patients (49%
versus 84%, Figure 3A). In contrast, the proportion receiving
only best supportive care was 16% among patients aged 45 to 59
years, but increased to 51% among those 75 years or older.
Although PCI was not often applied to patients with ED until 2006,
39% of patients aged 45 to 59 years who had received chemother-
apy underwent PCI in 2009. This proportion was 32% for those
aged 60 to 74 years and 25% for those 75 years or older.
Trends in Survival
Relative survival for the whole group has only slightly
improved, mainly since the mid-2000s. One-year relative
FIGURE 1. Trends in stage distribution of SCLC in the
Netherlands 1989 to 2009, according to gender.
FIGURE 2. Trends in age-standardized incidence rates (ESR)
of small cell lung cancer (SCLC) in the Netherlands, 1989 to
2009.
FIGURE 3. A, Primary treatment of SCLC in the Nether-
lands (2004–2009) by stage and age. BSC, best supportive
care, CT, chemotherapy, RT, radiotherapy, PCI, prophylactic
cranial irradiation. *Percentage of patients who received che-
motherapy. B, Trends in proportion chemoradiation for lim-
ited SCLC by age.
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survival increased slightly but not significantly from 26 to 32%
for males (p 0.09, Figure 4A) and from 35 to 41% for females
(p  0.14, Figure 4A), 3-year relative survival increased signif-
icantly from 5.5 to 9.2% for males (p  0.001) and from 6.5 to
14% for females (p  0.001), and 5-year survival increased
significantly from 3.6 to 6.8% for males (p  0.001) and from
4.2 to 8.9% for females (p  0.001).
When stratifying according to stage, 1-year relative
survival for patients with LD was better in 2009 as compared
with 1989 (61% versus 39% for males and 67% versus 51%
for females, p  0.05). For those with ED, 1-year relative
survival has slightly increased from 14 to 19% for males and
from 20 to 27% for females (p  0.05).
One-year relative survival has only statistically signif-
icantly increased over time for patients aged 45 to 59 years
(p  0.01, Figure 4B, C): from 37 to 51% among males and
from 42 to 51% among females. For those 60 years or older,
survival has not significantly improved (p 0.10 and 0.08 for
males and females aged 60 to 74 years, respectively, and p 
0.49 and p  0.68 for males and females older than 75 years,
respectively).
DISCUSSION
The incidence of SCLC further decreased among men
but increased among women. There was a trend toward more
extensive disease. Despite better staging techniques and in-
creased use of new treatment modalities, survival of the total
group of unselected patients with SCLC has only improved
for patients aged 45 to 59 years.
Trends in Incidence
Due to smoking behavior, the incidence of lung cancer
among Dutch men increased dramatically until the early
1980s, whereafter it has declined. In the meantime, there has
been a shift from squamous cell and small cell carcinoma to
adenocarcinoma.1,16 The incidence of lung cancer among
women used to be much lower than the incidence among
men, but since the early 1980s, the incidence among women
(all histological subtypes) has been increasing markedly to
the point that the incidence rates for men and women have
converged toward each other. However, recently the inci-
dence of lung cancer, including SCLC, among young Dutch
women has started to decrease.17
Our study has shown that the proportion of patients
diagnosed with ED has increased since the late 1990s. The
same trend has been described in a recent study.16 This stage
shift is probably caused by the introduction of improved
diagnostic techniques, such as improved availability and
quality of computer tomography (CT) and magnetic reso-
nance imaging (MRI), and positron emission tomography
(PET). In the Netherlands, brain CT with contrast or brain
MRI is standard of care to determine whether or not brain
metastases are present. Introduction of PET scanning differed
between regions and took place between the early 1990s and
the early 2000s. With the availability of these techniques, the
detection of previously occult distant metastases is facilitated,
which has led to an upstaging from limited to extensive
disease. The fact that overall 1-year survival of the total
group did not significantly increase, but 1-year survival of
both limited and ED has improved over time, is in line with
a stage shift.
FIGURE 4. Trends in 1-year relative survival from SCLC in
the Netherlands 2004 to 2009, by gender and age. A, By
gender. B, Males by age. C, Females by age.
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Trends in Treatment Strategies
In our study, the proportion of patients with LD receiv-
ing chemoradiation increased since the early 1990s, in accor-
dance with the previously published studies. Clinical trials
have shown that chemoradiation for LD has resulted in better
local control and overall survival compared with chemother-
apy alone.18–22 After publication of a Norwegian study show-
ing that a novel multimodal regimen is effective and well
tolerated, concurrent chemoradiation became the new stan-
dard.23 Trials of newer chemotherapy variations have failed to
produce a regimen that is clearly superior to the two-drug
combination of etoposide and cisplatin, which has gradually
become the standard of care for both limited and extensive
disease.18 Nowadays, standard treatment for LD SCLC in the
Netherlands is cisplatin-etoposide (CE) combined with con-
current radiation therapy starting on the first day of chemo-
therapy course 2. Sometimes cisplatin was substituted by
carboplatin.24–26
In our study, the application of PCI increased over time.
The brain remains an important site of recurrence. With im-
proved systemic treatment and longer survival, the frequency of
brain metastases increases. PCI substantially reduces the risk of
brain recurrence, but the effect on survival has been debated.11,27
In the Netherlands, PCI is applied in case of a partial response or
stable disease to chemotherapy or chemoradiation. Because this
is an observational study, we cannot evaluate the individual
effect of PCI on survival in unselected patients.
In accordance with previous studies,28–34 elderly pa-
tients tend to receive less intensive treatment, either due to
dose reductions of chemotherapy cycles or due to dose
reductions/less frequent use of radiotherapy.28,29,32,35–42 The
less intensive treatment could be related to expected toxicity.
Previous studies report inconsistent findings with regard to
increased toxicity for elderly patients with SCLC and for
those with serious comorbidity. Most of these studies were
clinical trials and may therefore be biased due to trial eligi-
bility criteria (most of them only including relatively healthy
elderly patients). A recent publication from our group has
shown that 60 to 75% of elderly SCLC patients who were
selected for chemotherapy or combined chemoradiation de-
veloped toxicity, and two thirds of patients could not com-
plete the full chemotherapy.34
Trends in Prognosis
Patients with SCLC have a very poor prognosis. In
most cases, death from recurrent disease occurs within 2
years of diagnosis. Previous studies have shown some prog-
ress in survival since the introduction of chemotherapy:
1-year relative survival rates improved from 18% in the
1970s to more than 30% in the 1990s for patients up to 70
years and from 9% to almost 20% for the elderly.4,7,43–45 We
have shown that survival for the group of patients with SCLC
as a whole has not further improved since the early 1990s,
except for age group 45 to 59 years since the mid-2000s.
However, when stratifying according to stage, 1-year relative
survival for both patients with LD and ED has improved, as
was also found in an American study.46 The improvements in
survival for each stage group with lacking improvement for
the whole group might be explained by stage migration. The
increased survival for patients aged 45 to 59 years might also
be explained by improved treatment strategies.
In the Netherlands, prognosis was more favorable for
females as compared with males. In Europe, 5-year survival
for lung cancer in general used to be somewhat better for
females than males.47 This might be due to the fact that SCLC
was diagnosed earlier among females (results from this study)
and also due the fact that the mean age of female lung cancer
patients was lower than that of male patients. Furthermore,
males have more tobacco-related comorbidity than females.48
A favorable prognosis for females was also found for many
other tumors.49,50
Relative survival of SCLC clearly decreased with in-
creasing age. This was also found in previous studies.28,35 The
poorer prognosis among the elderly might be explained by
several factors: an increased risk of mortality due to smoking-
related comorbid conditions, such as chronic obstructive
pulmonary disease (COPD), or a poor performance status,
death due to a higher risk of complications of treatment (also
related to decreased organ functions51,52), or death of cancer
due to less aggressive treatment. The latter could lead to a
lower response rate and a higher recurrence rate among
elderly patients. Previous studies indicated that prognosis for
elderly patients with LD SCLC was not worse compared with
younger patients after adjustment for differences in treatment
modality, gender, and comorbidity.29,30,35,38,53 The fact that
survival has not significantly improved for elderly patients in
our study indicates that elderly did not yet benefit from
improved treatment strategies.
Our population-based study made use of a large, high-
quality population-based dataset to report on an unselected
group of patients with SCLC, and this enables reliable com-
parison with other studies of unselected patients. Interpreting
the prognostic effects of the different treatment modalities
would be more difficult, though, because selection for treat-
ment by the physician has played an important role. Caution
is therefore warranted in comparing the outcomes with those
from selected patient groups in clinical trials.
CONCLUSIONS
The diverging trends in incidence of SCLC between
Dutch males and females followed the trends in smoking
behavior in the past. Improved staging resulted in improved
survival for both stage groups, while survival of the total
group has only significantly improved for patients aged 45 to
59 years. The latter is possibly related to improved treatment
strategies. As survival is still very poor, prevention of lung
cancer remains important.
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